351 related articles for article (PubMed ID: 11505639)
1. [About side effects of platinum drugs].
Waszkiewicz K
Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
[TBL] [Abstract][Full Text] [Related]
2. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin.
Enrique E; Malek T; Castelló JV; de Mateo JA
Ann Allergy Asthma Immunol; 2008 Jan; 100(1):86. PubMed ID: 18254488
[No Abstract] [Full Text] [Related]
4. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research.
Ali BH; Al Moundhri MS
Food Chem Toxicol; 2006 Aug; 44(8):1173-83. PubMed ID: 16530908
[TBL] [Abstract][Full Text] [Related]
5. [Cisplatin].
Millá A; Grau JJ; Estapé J
Med Clin (Barc); 1983 Feb; 80(6):283-8. PubMed ID: 6345956
[No Abstract] [Full Text] [Related]
6. Adverse effects of cytotoxics-platinum agents.
Selvaratnam G; Philips RH; Mohamed AK; Radzi A
Adverse Drug React Toxicol Rev; 1997 Aug; 16(3):171-97. PubMed ID: 9512763
[No Abstract] [Full Text] [Related]
7. Understanding platinum-induced ototoxicity.
Langer T; am Zehnhoff-Dinnesen A; Radtke S; Meitert J; Zolk O
Trends Pharmacol Sci; 2013 Aug; 34(8):458-69. PubMed ID: 23769626
[TBL] [Abstract][Full Text] [Related]
8. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
9. Toxicities of the platinum antineoplastic agents.
Markman M
Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
[TBL] [Abstract][Full Text] [Related]
10. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
11. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
Launay-Vacher V; Rey JB; Isnard-Bagnis C; Deray G; Daouphars M;
Cancer Chemother Pharmacol; 2008 May; 61(6):903-9. PubMed ID: 18317762
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin: a review of toxicities and therapeutic applications.
Barabas K; Milner R; Lurie D; Adin C
Vet Comp Oncol; 2008 Mar; 6(1):1-18. PubMed ID: 19178659
[TBL] [Abstract][Full Text] [Related]
13. Modern methods for diagnosis and monitoring of nephrotoxicity during antitumor therapy with platinum derivatives.
Lyubimova NV; Topchieva SV; Averinova SG; Kashkadaeva AV; Gorbunova VA; Shiryaev SV; Kushlinskii NE
Bull Exp Biol Med; 2000 Sep; 130(9):886-91. PubMed ID: 11177273
[TBL] [Abstract][Full Text] [Related]
14. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
Yonezawa A; Inui K
Biochem Pharmacol; 2011 Mar; 81(5):563-8. PubMed ID: 21144842
[TBL] [Abstract][Full Text] [Related]
15. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
16. Nephrotoxicity of common drugs used by urologists.
Bennett WM; Porter GA
Urol Clin North Am; 1990 Feb; 17(1):145-56. PubMed ID: 2407013
[TBL] [Abstract][Full Text] [Related]
17. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
18. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity.
Chirino YI; Pedraza-Chaverri J
Exp Toxicol Pathol; 2009 May; 61(3):223-42. PubMed ID: 18986801
[TBL] [Abstract][Full Text] [Related]
19. [Renal complications of anti-cancer chemotherapy].
Fillastre JP; Moulin B; Godin M; Josse S
Pathol Biol (Paris); 1986 Nov; 34(9):1013-28. PubMed ID: 3543812
[TBL] [Abstract][Full Text] [Related]
20. [Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].
Matsuoka A; Ando Y
Gan To Kagaku Ryoho; 2017 Mar; 44(3):200-203. PubMed ID: 28292990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
